Ruti Aga's Six-Year Ban: How a Forged Prescription Turned a Two-Year Case Into Career Death

Ruti Aga's case did not begin with six years. It began with 2+4. The Athletics Integrity Unit statement, released on Thursday, joins two separate violations into one long sanction: two years for the presence of a prohibited substance, four years for tampering with the investigation. That arithmetic is the story. Aga won a half marathon in China in March and returned a positive sample. The substance was methylprednisolone. She cited a knee injury. Then came the paper trail: the prescription was written by a family member who was not a registered doctor, using what he called an old prescription pad from a former workplace. She had been provisionally suspended since 10 September, and the same date now marks the start of a six-year ban.

A technical correction comes first, because the case turns on it. Several reports call methylprednisolone a prohibited steroid and describe it as performance-enhancing under WADA rules. That is imprecise. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9, not an anabolic steroid under S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection out of competition is not automatically a violation. It becomes one when residues are present in an in-competition sample. In road racing, the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. The defence pathway was route and timing, not the name of the drug.

Aga is 32. In Ethiopian women's marathon depth, that is late peak or the beginning of decline. Her record includes the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. External records list 2:18:34 from Berlin 2026 and 2:20:40 from Tokyo 2026, but the primary source in this report does not give a personal best. Where the source is silent, I will not turn inference into fact. The 2026 title belongs to a period with no proven earlier violation, so it does not automatically fall. The source does not state the disqualification scope, but standard AIU practice voids the result and prize money from the competition where the sample was collected.

The sanction arithmetic is simple and consequential. Two years cover presence; four years cover tampering. The two-year figure indicates a Specified Substance finding without proven intent. The four-year figure indicates that the forged prescription and misleading answers were treated as fully culpable. A no-significant-fault argument could have reduced the presence sanction. It did not happen. Backdating to 10 September is procedural, not a discount: provisional suspension time counts against the ban, and the athlete gains nothing real from it. The six-year figure survives an audit because it is a document sanction, not a drug sanction.

The forged-prescription chain contains three separate verification failures. The doctor was a family member with no medical registration. The clinic named on the prescription did not exist. The clinic explicitly disowned the old prescription pad. This is not a filing error. It is a medical-governance failure. A properly managed knee injection would have involved a credentialed team physician, real records, a TUE application where needed, and route-specific washout timing before competition. None of that appears. When an athlete lacks real medical records, the entourage manufactures paper; that is the signal in this case.

The Chinese label race is the second front. The source gives no mark for the March half marathon, so inferring form from the word won would be dirty data. What is clear is that a win implies an elite field, and an elite field implies in-competition testing. For East African marathoners, Chinese label races are a reliable income tier between Majors: appearance fees, low race count, low risk. That same tier is now one of the AIU's highest-yield testing grounds. The appearance-fee economy and the testing economy are colliding in the same races. The performance is secondary here. The disqualification is the story.

Ethiopian women's marathon depth is so extreme that a 2:18–2:20 athlete is not automatically selectable. Aga's removal does not change national-team medal capacity by any measurable margin. Her three Major second places were commercial-tier results, not championship conversions. A six-year ban at 32 removes the 2028 Olympic cycle entirely. A return would come at roughly 38. At that age, with a doping record, in Ethiopian depth, selection is implausible. Her record is now bifurcated: the 2026 Tokyo title and three Major podiums remain the record of a genuinely elite marathoner, while the ban makes her commercially radioactive in a sport where distance-running sponsorship is already thin.

A contrarian question is necessary. Six years for an S9 glucocorticoid looks disproportionate, because the substance has no proven endurance benefit. The ban is not for the drug. It is for the cover-up that followed. With genuine medical records, Aga could have argued route, timing and knee pathology. The forged prescription closed the one defence that could have worked. Media reports that called it a steroid distorted the comparison further; this is not an anabolic-steroid category case. I do not need to hunt for a hidden discrepancy here. The accepted six-year figure survives scrutiny. The limit is that the source does not give the year of the March race or the exact end date of the ban; confidence is high on structure, medium on the final date.

The next signal is clear: enforcement in road running now runs through document verification, not only sample collection. Informal medical networks serve many athletes in the same East African training clusters, so similar cases will recur. A CAS appeal window may exist, but a forgery finding is document-based and hard to overturn. The next time a marathoner explains a knee injection, the question will not be what the drug was. It will be who stamped the prescription, which clinic was named, and who saw the paper before the AIU did.